 Clinical Study
November 10, 2025
In the evolving landscape of oncology and infectious disease management, AIM ImmunoTech Inc. (NYSE American: AIM) has recently captured attention by detailing significant findings from completed clinical trials. The company, primarily known for its innovative immunotherapy, Ampligen (rintatolimod), has contributed t...
|
Clinical Study
November 10, 2025
AnaptysBio s Rosnilimab Phase 2 Trial Falls Short But Signals Resilience in Immunology Innovation San Diego, Nov. 10, 2025 - In a significant update from AnaptysBio, Inc. (Nasdaq: ANAB), a prominent clinical-stage biotechnology company centered on pioneering immunology therapeutics, the much-anticipated results fro...
|
Business Update
November 10, 2025
PALO ALTO, Calif. D-Wave Quantum Inc. (NYSE: QBTS) has firmly established itself as a trailblazer in the quantum computing sphere, showcasing advanced technologies that are poised to revolutionize high-performance computing (HPC). At the upcoming SC25 international conference, dedicated to HPC, networking, storage...
|
|
 Business Update
November 10, 2025
Revolutionizing Industry: Aptiv and Robust.AI s Strategic Partnership to Develop AI-Powered Collaborative RobotsIn a groundbreaking collaboration that is set to reshape the landscape of industrial automation, Aptiv PLC (NYSE: APTV) and Robust.AI have announced their strategic partnership to develop AI-powered colla...
 Business Update
November 10, 2025
Revvity’s Strategic Moves to Enhance Scientific Software and Genomic Diagnostics WALTHAM, Mass. In an ambitious bid to bolster its position in the analytical and genomic landscapes, Revvity, Inc. (NYSE: RVTY), has announced significant operational advancements through targeted acquisitions and strategic collabor...
|
|
Our most Popular Articles
|
Business Update
January 4, 2025
McKesson s Strategic Shift: Divesting Some, Growing MoreOn December 30, 2024, McKesson Corporation, a leading name in healthcare services and information technology, finalized the sale of its Canadian subsidiaries, Rexall and Well.ca, to Birch Hill Equity Partners. This move, initially announced in September, signi...
|
Product Service News
March 19, 2025
In a remarkable convergence of cutting-edge technology and robust financial performance, Coherent Corp. (NYSE: COHR), a trailblazer in the field of photonics, has been recognized as a pivotal collaborator within NVIDIA s ecosystem for co-packaged optics (CPO). This innovative partnership was unveiled at the recent G...
|
Announcement
June 12, 2025
Organon Shareholder Alert: Investors Urged to Act Amid Class Action Lawsuit Due to Underperformance In a noteworthy development for shareholders of Organon & Co. (NYSE: OGN), ClaimsFiler has issued a reminder to investors who have suffered losses exceeding $100,000 to file lead plaintiff applications in an ongoing c...
|
|
|
Company News
|
Clinical Study
November 10, 2025
AnaptysBio s Rosnilimab Phase 2 Trial Falls Short But Signals Resilience in Immunology Innovation San Diego, Nov. 10, 2025 - In a significant update from AnaptysBio, Inc. (Nasdaq: ANAB), a prominent clinical-stage biotechnology company centered on pioneering immunology therapeutics, the much-anticipated results fro...
|
Business Update
November 10, 2025
PALO ALTO, Calif. D-Wave Quantum Inc. (NYSE: QBTS) has firmly established itself as a trailblazer in the quantum computing sphere, showcasing advanced technologies that are poised to revolutionize high-performance computing (HPC). At the upcoming SC25 international conference, dedicated to HPC, networking, storage...
|
Business Update
November 10, 2025
In a significant advancement in the fight against tuberculosis (TB), AN2 Therapeutics, Inc., a pioneering biopharmaceutical company based in Menlo Park, California, has announced a research collaboration with the global biopharmaceutical giant GlaxoSmithKline (GSK). This partnership aims to develop novel therapies u...
|
|
|
Company News
 Business Update
November 10, 2025
|
Company News
 Product Service News
November 7, 2025
|
Company News
 Contract
November 7, 2025
|
More Company News
|
Clinical Study
November 7, 2025
|
Product Service News
November 7, 2025
|
Business Update
November 7, 2025
|
Business Update
November 7, 2025
|
Clinical Study
November 7, 2025
|
Clinical Study
November 7, 2025
|
Clinical Study
November 7, 2025
|
Clinical Study
November 7, 2025
|
Clinical Study
November 7, 2025
|
Clinical Study
November 7, 2025
|
|
|
|
Related News
|
Product Service News
|
Business Update
|
|
Stocks
|
Business Update
|
Business Update
|
Business Update
|
|
|
|
Business News
|
|
Business Update
Revolutionizing Industry: Aptiv and Robust.AI s Strategic Partnership to Develop AI-Powered Collaborative RobotsIn a groundbreaking collaboration that is set to reshape the landscape of industrial automation, Aptiv PLC (NYSE: APTV) and Robust.AI have announced their strategic partnership to develop AI-powered colla...
|
|
Business Update
Revvity’s Strategic Moves to Enhance Scientific Software and Genomic Diagnostics WALTHAM, Mass. In an ambitious bid to bolster its position in the analytical and genomic landscapes, Revvity, Inc. (NYSE: RVTY), has announced significant operational advancements through targeted acquisitions and strategic collabor...
|
 Business Update
In a landmark development for breast cancer patients and the realm of precision oncology, Personalis, Inc. (Nasdaq: PSNL) has announced Medicare coverage for its ultrasensitive NeXT Personal test, designed for monitoring cancer recurrence. This announcement represents a significant advancement in cancer surveillance...
|
 Business Update
In a forward-thinking move aimed at enhancing ride efficiency and expanding driver opportunities, Lyft Inc. (NASDAQ: LYFT) has announced a strategic partnership with Curb, a leader in the licensed taxi ride-hailing market. This collaboration is poised to integrate Lyft riders with Curb’s extensive network of taxi ...
|
 Clinical Study
In the evolving landscape of oncology and infectious disease management, AIM ImmunoTech Inc. (NYSE American: AIM) has recently captured attention by detailing significant findings from completed clinical trials. The company, primarily known for its innovative immunotherapy, Ampligen (rintatolimod), has contributed t...
|
Our Most Popular Articles
|
 Business Update
McKesson s Strategic Shift: Divesting Some, Growing MoreOn December 30, 2024, McKesson Corporation, a leading name in healthcare services and information technology, finalized the sale of its Canadian subsidiaries, Rexall and Well.ca, to Birch Hill Equity Partners. This move, initially announced in September, signi...
|
 Product Service News
In a remarkable convergence of cutting-edge technology and robust financial performance, Coherent Corp. (NYSE: COHR), a trailblazer in the field of photonics, has been recognized as a pivotal collaborator within NVIDIA s ecosystem for co-packaged optics (CPO). This innovative partnership was unveiled at the recent G...
|
 Announcement
Organon Shareholder Alert: Investors Urged to Act Amid Class Action Lawsuit Due to Underperformance In a noteworthy development for shareholders of Organon & Co. (NYSE: OGN), ClaimsFiler has issued a reminder to investors who have suffered losses exceeding $100,000 to file lead plaintiff applications in an ongoing c...
|
More News
|
 Clinical Study
AnaptysBio s Rosnilimab Phase 2 Trial Falls Short But Signals Resilience in Immunology Innovation San Diego, Nov. 10, 2025 - In a significant update from AnaptysBio, Inc. (Nasdaq: ANAB), a prominent clinical-stage biotechnology company centered on pioneering immunology therapeutics, the much-anticipated results fro...
|
 Business Update
PALO ALTO, Calif. D-Wave Quantum Inc. (NYSE: QBTS) has firmly established itself as a trailblazer in the quantum computing sphere, showcasing advanced technologies that are poised to revolutionize high-performance computing (HPC). At the upcoming SC25 international conference, dedicated to HPC, networking, storage...
|
 Business Update
In a significant advancement in the fight against tuberculosis (TB), AN2 Therapeutics, Inc., a pioneering biopharmaceutical company based in Menlo Park, California, has announced a research collaboration with the global biopharmaceutical giant GlaxoSmithKline (GSK). This partnership aims to develop novel therapies u...
|
|
Business Update
In the ever-evolving landscape of medical technology, TriSalus Life Sciences continues to push the boundaries of cancer treatment. This innovative oncology company, known for its commitment to integrating novel delivery technologies with conventional therapies, is turning the spotlight on its promising TriNav Infusi...
|
 Product Service News
Advanced Augmented Reality Sub-Systems: Precision Optics Innovates Fighter Pilot Training In a significant leap forward for military technology, Precision Optics Corporation, Inc. (NASDAQ: POCI) has secured a pivotal product development agreement aimed at transforming fighter pilot training. Announced on 7 November ...
|
 Contract
Environmental Tectonics Corporation Expands Its Portfolio Amid Positive Operational Indicators Environmental Tectonics Corporation (ETC), a firm known for its contributions to environmental testing and simulation systems, has recently secured significant contracts that are poised to bolster its market position. On N...
|
 Clinical Study
Recent advancements in the field of oncology have introduced novel therapies aimed at improving survival outcomes for patients with refractory soft tissue sarcomas, a notoriously difficult-to-treat group of tumors. Among these, bio-therapeutic innovations such as Mecbotamab Vedotin (Mec-V), an antibody-drug conjugat...
|
 Product Service News
On November 7, 2025, IP Strategy (Nasdaq: IPST), a trailblazer in the realm of intellectual property and cryptocurrency, issued a momentous statement applauding the successful launch of the Aria token ($ARIAIP) on the Story IP blockchain. This milestone not only signifies a pivotal expansion of digital asset capabil...
|
 Business Update
In a significant move to bolster educational opportunities in the Chicagoland area, the Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), recently announced a $2.6 million grant to Northwestern University s School of Education and Social Policy. This partnership is set to enhance scie...
|
 Business Update
Stewart Information Services Strengthens Position in Real Estate Sector with Acquisition of Mortgage Contracting Services In an ambitious move to enhance its real estate services and solidify its standing in the mortgage sector, Stewart Information Services Corporation (NYSE: STC) has announced its intent to acquire...
|
 Clinical Study
In the ever-evolving landscape of cancer immunotherapy, the latest data unveiled by Coherus Oncology at the Society for Immunotherapy of Cancer (SITC) conference highlights a promising leap forward in precision medicine. CHS-114, a groundbreaking anti-CCR8 cytolytic antibody, demonstrates significant potential in al...
|
 Clinical Study
: MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on innovative allogeneic invariant natural killer T (allo-iNKT) cell therapies, showcased promising clinical data on its lead candidate, agenT-797, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025. The findings indicat...
|
 Clinical Study
At the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), IO Biotech presented compelling pre-clinical data on its additional therapeutic cancer vaccine candidates. This research highlights the company s commitment to advancing immunotherapeutic approaches in oncology. Alongside this, recent market performance indicators suggest a positive outlook for IO Biotech, outperforming broader market trends and demonstrating resilience among its competitive peers.The landscape of cancer treatment is continuously evolving, with immunotherapy leading as a promising frontier. At the recent SITC 2025 Annual Meeting, IO Biotech Inc. emerged as a pivotal player by unveiling new pre-clinical data that underscores the potential of their therapeutic cancer vaccine candidates. The findings not only enhance our understanding of cancer immunotherapy but also position IO Biotech as a formidable competitor in the biopharmaceutical sector.
|
 Clinical Study
Expanding the Horizons of Immunotherapy: Advances in Werewolf Therapeutics’ PREDATOR and INDUKINE Platforms The field of immunotherapy is witnessing a paradigm shift with groundbreaking innovations designed to enhance therapeutic efficacy while minimizing adverse effects. Werewolf Therapeutics, a prominent biotec...
|
 Clinical Study
: This article delves into the recent developments and promising advancements announced by Elicio Therapeutics, a clinical-stage biotechnology leader in cancer immunotherapy. By examining the emerging data from their ongoing Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on ELI-004, we assess their im...
|
|
Clinical Study
Nurix Therapeutics has recently made significant strides in the field of oncology and immunology with their pioneering research and development programs. Building upon a series of compelling studies and validatory preclinical data, the company has showcased the promising potential of their investigational agents NX-...
|
|
|
|
|
